Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia

Diabetes Technology and Therapeutics

Volumn 10, Issue 4, 2008, Pages 273-277

  Davies, Melanie J ^a,d   Derezinski, Tadeusz ^b   Pedersen, Claus Bang ^c   Clauson, Per ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Outpatient Clinic   (Poland)

^c NOVO NORDISK A S   (Denmark)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; RISK; WEIGHT LOSS;

EID: 50049096963     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0282     Document Type: Article

References (40)

1. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
4. Davies M: The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl 2):S14-S22.
5. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265.
6. Carver C: Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006;32:910-917.
7. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the Diabetes Control and Complications Trial. JAMA 1998;280:140-146.
8. Makimattila S, Nikkila K, Yki-Jarvinen H: Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:406-412.
9. Carlson MG, Campbell PJ: Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700-1707.
10. Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S: A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in Type 2 diabetes. J Intern Med 1994;236:305-313.
11. Schwartz MW: Enhanced: staying slim with insulin in mind. Science 2000;289:2066-2067.
12. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR: Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-2125.
13. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. Diabetes Care 1988;11:567-573.
14. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-596.
15. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-629.
16. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-1087.
17. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J: Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-736.
18. Standl E, Lang H, Roberts A: The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004;6:579-588.
19. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW: Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82.
20. Pieber TR, Draeger E, Kristensen A, Grill V: Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-857.
21. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
22. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
23. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274.
24. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P: The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-1504.
25. Kurtzhals P: Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004;28(Suppl 2):S23-S28.
26. Heise T, Nosek L, Ronn BB, Rønn B, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620.
27. Heller S, Kim H, Draeger E: Within-person variation in fasting blood glucose is correlated to incidence of hypoglycaemia in people with Type 1 diabetes treated with insulin detemir and NPH insulin [abstract]. Diabetologia 2004;47(Suppl 1):A303.
28. Robertson KJ, Schonle E, Gucev Z, Mordhorst L, Tamer SC, Gall MA, Ludvigsson J: Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycaemia [abstract]. Diabetologia 2004;47(Suppl 1):A32.
29. Kolendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR: Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006;23:729-735.
30. Hermansen K, Davies M: Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diab Obes Metab 2007;9:209-217.
31. Home P, Kurtzhals P: Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7:325-343.
32. Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group: Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-770.
33. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583-588.
34. Heller SR, Amiel SA, Mansell P: Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999;22:1607-1611.
35. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
36. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL: Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005;48:420-426.
37. Hopkins DF, Williams G: Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity. Diabet Med 1997;14:1044-1050.
38. Pliquett RU, Fuhrer D, Falk S, Zysset S, von Cramon DY, Stumvoll M: The effects of insulin on the central nervous system - focus on appetite regulation. Horm Metab Res 2006;38:442-446.
39. Hennige AM, Metzinger E, Fritsche A, Häring H-A: Tissue selectivity of insulin detemir action [abstract]. Diabetes 2005;54(Suppl 1):A336.
40. Tschritter O, Porubska K, Hennige A, Preissl H, Lutzenberger W, Fritsche A, Häring H: Neuronal activation of the human cerebral cortex by administration of insulin detemir compared to human insulin [abstract]. Diabetologia 2005;48(Suppl 1):A256.